Patient characteristics
| Characteristic . | . |
|---|---|
| Median age, y (range) | 54.5 (23-60) |
| Sex, M:F | 16:14 |
| Median WBC, ×109/L (range) | 14.4 (1.5-211) |
| Median platelet count, ×109/L (range) | 57 (9-175) |
| Cytogenetics, no. subjects (%)* | |
| Intermediate, diploid, abn(12p),† +8,† +21 | 15 (50) |
| Adverse complex, −7/7q, 11q23,‡ t(6;9) | 13 (43) |
| Unknown add(18p), t(2:11)(q31;p15) | 2 (7) |
| FLT3-ITD, no. subjects (%) | 4 (13) |
| Antecedent hematologic disorder, no. subjects (%) | 8 (27) |
| WBC, no. subjects (%) | |
| > 100 000 | 5 (17) |
| > 50 000 | 8 (27) |
| ≥ 1 Adverse molecular feature, no. subjects (%)§ | 17 (57) |
| ≥ 1 Adverse feature, no. subjects (%)¶ | 25 (83) |
| Characteristic . | . |
|---|---|
| Median age, y (range) | 54.5 (23-60) |
| Sex, M:F | 16:14 |
| Median WBC, ×109/L (range) | 14.4 (1.5-211) |
| Median platelet count, ×109/L (range) | 57 (9-175) |
| Cytogenetics, no. subjects (%)* | |
| Intermediate, diploid, abn(12p),† +8,† +21 | 15 (50) |
| Adverse complex, −7/7q, 11q23,‡ t(6;9) | 13 (43) |
| Unknown add(18p), t(2:11)(q31;p15) | 2 (7) |
| FLT3-ITD, no. subjects (%) | 4 (13) |
| Antecedent hematologic disorder, no. subjects (%) | 8 (27) |
| WBC, no. subjects (%) | |
| > 100 000 | 5 (17) |
| > 50 000 | 8 (27) |
| ≥ 1 Adverse molecular feature, no. subjects (%)§ | 17 (57) |
| ≥ 1 Adverse feature, no. subjects (%)¶ | 25 (83) |
The majority of subjects had at least 1 adverse prognostic feature.
ECOG/SWOG criterion.2
abn(12p), +8 are considered adverse risk by CALGB.1
t(11;19)(q23;p13.1), t(10;11)(p12;q23).
Adverse karyotype or FLT3-ITD.
Adverse molecular features or antecedent hematologic disorder, age ≥ 55, WBC > 50 000.